Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Edgar Ben‐Josef

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1292-9565; OpenAlex author ID A5061377078, A5108413597. Sources: ClinicalTrials.gov.

Their work

Papers
26 (first author 3, last author 7)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
106
Papers, trials and grants by year

2011: 2 papers · 2012: 5 papers · 2013: 2 papers, 1 trial · 2014: 3 papers, 1 trial · 2015: 1 paper · 2016: none · 2017: 2 papers · 2018: 2 papers · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 26

  1. High SMAD4 Expression is Associated With Improved Clinical Outcomes in Patients With Resectable Pancreatic Cancer: An Analysis of NRG Oncology/RTOG 9704. Last author DOI 10.1016/j.ijrobp.2026.09.014↗
  2. A phase 1 dual-dose escalation study of radiation and nab-paclitaxel in patients with unresectable and borderline resectable pancreatic cancer. Last author DOI 10.1002/cncr.35936↗
  3. SMAD4 loss predicts worse overall and distant metastasis-free survival in patients with resected pancreatic adenocarcinoma. Last author DOI 10.1002/cncr.35058↗
  4. Proton radiation boosts the efficacy of mesothelin-targeting chimeric antigen receptor T cell therapy in pancreatic cancer. Co-author DOI 10.1073/pnas.2403002121↗
  5. Carbon ion radiotherapy as definitive treatment in locally recurrent pancreatic cancer. First author DOI 10.1007/s00066-021-01827-9↗
  6. Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreatic Cancer. Last author DOI 10.1097/coc.0000000000000854↗
  7. Impact of FAPI-PET/CT on Target Volume Definition in Radiation Therapy of Locally Recurrent Pancreatic Cancer. Co-author DOI 10.3390/cancers13040796↗
  8. Radiographic Response of Vessel Involvement and Resectability After Neoadjuvant Chemoradiation in Patients With Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000746↗
  9. Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704. Co-author DOI 10.1634/theoncologist.2019-0562↗
  10. A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer. Last author DOI 10.1007/s00280-018-3519-6↗
  11. Prognostic Value of c-MET Expression in Patients With Pancreatic Cancer Receiving Adjuvant and Neoadjuvant Chemoradiation Therapy. Co-author DOI 10.1016/j.ijrobp.2017.10.030↗
  12. Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-16-0870↗
  13. Proton beam reirradiation for locally recurrent pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo.2017.03.04↗
  14. Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer. First author DOI 10.1038/srep10867↗
  15. Quality of life in a prospective, multicenter phase 2 trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or bor… Co-author DOI 10.1016/j.ijrobp.2014.05.053↗
  16. A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic cancer. Co-author DOI 10.1016/j.tranon.2014.07.005↗
  17. DEPTOR has growth suppression activity against pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.2659↗
  18. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. First author DOI 10.1002/cncr.28117↗
  19. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiati… Last author DOI 10.1016/j.ijrobp.2012.11.020↗
  20. Radiation therapy with full-dose gemcitabine and oxaliplatin for unresectable pancreatic cancer. Last author DOI 10.1016/j.ijrobp.2011.08.022↗
  21. A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pa… Co-author DOI 10.1016/j.ijrobp.2012.02.051↗
  22. Radiotherapy improves survival in unresectable pancreatic cancer: small trial but big (and credible) results. Co-author DOI 10.1200/jco.2011.40.9771↗
  23. Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? Co-author DOI 10.1634/theoncologist.2011-0268↗
  24. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. Co-author DOI 10.6004/jnccn.2012.0073↗
  25. Radiotherapy: the importance of local control in pancreatic cancer. Co-author DOI 10.1038/nrclinonc.2011.182↗
  26. Role of α(5)β(1) Integrin Up-regulation in Radiation-Induced Invasion by Human Pancreatic Cancer Cells. Co-author DOI 10.1593/tlo.11133↗

Trials 2

  1. A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer Principal investigator NCT02207465↗
  2. A Pilot Study to Evaluate Radiotherapy-Induced Anti-Tumor Immunity in Metastatic Carcinoma of the Pancreas Principal investigator NCT01985958↗

Closest collaborators

The 25 strongest of 106 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. John Peter Plastaras · 5 shared papers, 2017–2025 · strength 0.61
  2. James M. Metz · 5 shared papers, 2017–2025 · strength 0.61
  3. Patrick Naumann · 3 shared papers, 2020–2022 · strength 0.42
  4. Jakob Liermann · 3 shared papers, 2020–2022 · strength 0.42
  5. Jürgen Debus · 3 shared papers, 2020–2022 · strength 0.42
  6. Uri Amit · 2 shared papers, 2024–2025 · strength 0.40
  7. Mark H. O’Hara · 3 shared papers, 2018–2025 · strength 0.37
  8. Mark M. Zalupski · 9 shared papers, 2012–2018 · strength 0.37
  9. Theodore Steven Lawrence · 8 shared papers, 2011–2018 · strength 0.35
  10. Terence Marques Williams · 4 shared papers, 2011–2026 · strength 0.33
  11. William F. Regine · 2 shared papers, 2020–2026 · strength 0.32
  12. Michael G. Haddock · 2 shared papers, 2020–2026 · strength 0.32
  13. Klaus K Herfarth · 2 shared papers, 2021–2022 · strength 0.30
  14. Charles M. Vollmer · 2 shared papers, 2018–2025 · strength 0.27
  15. Hyun Kim · 1 shared paper, 2026 · strength 0.24
  16. Chandan Guha · 1 shared paper, 2026 · strength 0.24
  17. Ryan N. Robb · 1 shared paper, 2026 · strength 0.24
  18. Lauren E. Henke · 1 shared paper, 2026 · strength 0.24
  19. Thomas Benjamin Karasic · 1 shared paper, 2025 · strength 0.21
  20. Andre A. Konski · 1 shared paper, 2025 · strength 0.21
  21. Erica L. Carpenter · 1 shared paper, 2025 · strength 0.21
  22. Kim A. Reiss-Binder · 1 shared paper, 2025 · strength 0.21
  23. Constantinos Koumenis Nahum · 1 shared paper, 2024 · strength 0.19
  24. Carl H. June · 1 shared paper, 2024 · strength 0.19
  25. Emily J. Anstadt · 1 shared paper, 2024 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.